Educational information, not medical advice — ask your doctor or midwife.
Argireline is the trade name for acetyl hexapeptide-8 (originally called acetyl hexapeptide-3), a chain of six amino acids made in a laboratory. It was designed in the late 1990s to imitate a short section of SNAP-25, one of the proteins nerve endings use to release the signal that tells a muscle to contract. Because botulinum toxin also interferes with that same machinery — far more powerfully, and by injection into the muscle — Argireline picked up the marketing nickname "Botox in a bottle".
That nickname oversells it considerably. A peptide sitting on the skin surface has to cross the stratum corneum in meaningful amounts and reach the neuromuscular junctions of the facial muscles beneath the dermis. Acetyl hexapeptide-8 is water-loving and around 889 daltons, which makes deep penetration difficult, and no study has shown it actually reaching or relaxing facial muscle. Whatever benefit users see is more likely a modest surface effect on fine lines plus the hydration and film-forming action of the base formula.
What it does have going for it: it is cheap, stable in simple water-based serums, essentially non-irritating, and one of the few peptides with any published human data at all. It is a reasonable, low-risk addition to a routine — not a replacement for anything a dermatologist injects.
The proposed mechanism is competitive interference with the SNARE complex — the assembly of proteins that lets a nerve ending release acetylcholine onto a muscle fibre. Argireline's sequence mimics the N-terminal end of SNAP-25, so in a test tube it can slot into the complex and destabilise it, reducing neurotransmitter release. Botulinum toxin attacks the same system but cleaves SNAP-25 enzymatically and is delivered directly into muscle. For a topical peptide the chain of assumptions is much longer, and the key link — that enough peptide crosses intact skin to affect facial muscle in a living person — has not been demonstrated. A secondary and probably more relevant effect is simple hydration and temporary smoothing of the skin surface, which softens the look of fine lines regardless of any nerve activity.
Almost always sold in leave-on water-based serums, light emulsions and eye gels; it is not used in cleansers, where contact time is too short to matter. Be aware of a labelling quirk: products advertised as "Argireline Solution 10%" contain 10% of the supplier's pre-diluted trade solution, in which the peptide itself is only a small fraction. The actual peptide concentration is therefore far below 10%. Typical supplier guidance is 5–10% of the trade solution in a finished product. Peptides are more stable near neutral pH, so Argireline is usually formulated away from strong acids; it is commonly blended with other cosmetic peptides (matrixyl/palmitoyl pentapeptide, copper peptides) and humectants.
Argireline has no traditional or herbal lineage — it is a purely modern synthetic ingredient, patented by the Spanish biotech company Lipotec (later part of Lubrizol) around 1998–2001 and launched as a cosmetic active in the early 2000s. The frequently cited supporting study, published in 2002 in the International Journal of Cosmetic Science, applied a 10% acetyl hexapeptide-3 emulsion around the eyes of a small group of women for 30 days and reported roughly a quarter reduction in measured wrinkle depth by silicone imprint. It was small and industry-connected, but it made the ingredient famous, and Argireline became the template for the whole "neuropeptide" category of anti-ageing cosmetics.
Evidence grades and traditional-use labels are explained in our methodology. Nothing here is medical advice.
What it is typically used for, usual dose, cautions, and the study behind it where real trial data exists.
One email with the summary. We'll also send a short weekly evidence update — unsubscribe any time.
